Table 1.
Characteristics of patients in subgroups of accurate-T-staging, over-T-staging and under-T-staging
| Characteristics | Total | Accurate-T-staging | Over-T-staging | Under-T-staging | P Value |
|---|---|---|---|---|---|
| Cases | 551 | 392 (69.6%) | 109 (19.4%) | 50 (8.9%) | |
| Gender | 0.633 | ||||
| Female | 233 (42.3%) | 169 (43.1%) | 46 (42.2%) | 18 (36%) | |
| Male | 318 (57.7%) | 223 (56.9%) | 63 (57.8%) | 32 (64%) | |
| Age | 59.7 ± 13.4 | 60.2 ± 12.9 | 57.3 ± 14.4 | 61.3 ± 14.4 | 0.102 |
| BMI | 22.5 ± 4.19 | 22.5 ± 4.4 | 22.5 ± 3.8 | 22.5 ± 3.4 | 0.998 |
| Diabetes Mellitus | 0.157 | ||||
| No | 507 (93.9%) | 360 (93%) | 99 (94.3%) | 48 (100%) | |
| Yes | 33 (6.1%) | 27 (7%) | 6 (5.7%) | 0 (0%) | |
| CEA | 2.73 (0–255) | 2.7 (0–255) | 2.7 (0–197) | 4.5 (1–81) | 0.62 |
| CA199 | 10.2 (0–2188) | 10.64 (0–2188) | 7.59 (0–1156) | 10.35 (0–117) | 0.001 |
| Bowel Obstruction | 0.008 | ||||
| No | 471 (87.5%) | 350 (89.7%) | 88 (79.3%) | 44 (89.8%) | |
| Yes | 67 (12.5%) | 40 (10.3%) | 23 (20.7%) | 5 (10.2%) | |
| WBC | 6.53 ± 1.93 | 6.54 ± 1.91 | 6.53 ± 2.11 | 6.48 ± 1.71 | 0.984 |
| HB | 124.3 ± 21.5 | 125.0 ± 19.5 | 123.4 ± 24.4 | 121.1 ± 28.7 | 0.433 |
| PLT | 234.5 ± 78.4 | 237.6 ± 80.1 | 227.2 ± 74.5 | 226.4 ± 72.7 | 0.355 |
| ALB | 41.5 ± 6.30 | 41.6 ± 6.10 | 40.8 ± 6.96 | 42.2 ± 6.37 | 0.381 |
| Tumor Location | 0.186 | ||||
| Upper | 217 (39.4%) | 163 (41.6%) | 37 (33.9%) | 17 (34%) | |
| Middle | 141 (25.6%) | 101 (25.8%) | 24 (22%) | 16 (32%) | |
| Low | 193 (35%) | 128 (32.7%) | 48 (44%) | 17 (34%) | |
| Tumor Size (cm) | 4.07 ± 1.69 | 4.22 ± 1.70 | 3.76 ± 1.70 | 3.60 ± 1.37 | 0.005* |
| Histological Subtype | 1 | ||||
| Classic Adenocarcinoma | 505 (92%) | 359 (92.1%) | 100 (91.7%) | 46 (92%) | |
| Mucinous Adenocarcinoma | 44 (8%) | 31 (7.9%) | 9 (8.3%) | 4 (8%) | |
| Differentiation | 0.824 | ||||
| Grade 1/2 | 471 (92.4%) | 337 (92.1%) | 91 (94.8%) | 43 (89.6%) | |
| Grade 3/4 | 39 (7.6%) | 29 (7.9%) | 5 (5.2%) | 5 (10.4%) | |
| MMR Status | 0.823 | ||||
| pMMR | 350 (94.1%) | 17 (6.6%) | 4 (4.8%) | 1 (3.1%) | |
| dMMR | 22 (5.9%) | 239 (93.4%) | 80 (95.2%) | 31 (96.9%) | |
| Ras Mutation | 0.322 | ||||
| No | 496 (90%) | 355 (90.6%) | 99 (90.8%) | 42 (84%) | |
| Yes | 55 (10%) | 37 (9.4%) | 10 (9.2%) | 8 (16%) |
Abbreviations: BMI body mass index, CEA carcinoembryonic antigen, WBC white blood cell, HB hemoglobin, PLT plate, ALB albumin, pMMR mismatch repair-proficient, dMMR mismatch repair-deficient
*Post Hoc Test: Accurate-T-staging vs over-T-staging, P = 0.012; Accurate-T-staging vs under-T-staging, P = 0.015